Create a free QxMD account to take advantage of the features offered by Read like saving your papers and creating collections.

Get Started

Pazopanib

Ronald M Bukowski, Uma Yasothan, Peter Kirkpatrick

Nature Reviews. Drug Discovery 2010, 9 (1): 17-8

In October 2009, pazopanib (Votrient; GlaxoSmithKline)--a multikinase inhibitor with targets that include vascular endothelial growth factor receptors--was approved by the US FDA for the treatment of advanced renal cell carcinoma.

Full Text Links

Find Full Text Links for this Article

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Pazopanib: therapeutic developments. Suwicha Limvorasak, Edwin M Posadas Expert Opinion on Pharmacotherapy 2009, 10 (18): 3091-102

Pazopanib for the treatment of metastatic renal cell carcinoma. Amy M Pick, Kelly K Nystrom Clinical Therapeutics 2012, 34 (3): 511-20

Pazopanib for the treatment of renal cancer. Mhd Yaser Al-Marrawi, Brian Rini Expert Opinion on Pharmacotherapy 2011, 12 (7): 1171-89

Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Sidney V Keisner, Sachin R Shah Drugs 2011 March 5, 71 (4): 443-54

Everolimus and pazopanib: two new drugs for renal cell cancer. (no author information available yet) Medical Letter on Drugs and Therapeutics 2010 May 3, 52 (1337): 33-4

Safety and tolerability of pazopanib in the treatment of renal cell carcinoma. Andrea Zivi, Linda Cerbone, Federica Recine, Cora N Sternberg Expert Opinion on Drug Safety 2012, 11 (5): 851-9

Pazopanib: a review of its use in the management of advanced renal cell carcinoma. Paul L McCormack Drugs 2014, 74 (10): 1111-25

Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma. Ronald M Bukowski Expert Review of Anticancer Therapy 2010, 10 (5): 635-45

Pazopanib in renal cell carcinoma. Cora N Sternberg Clinical Advances in Hematology & Oncology: H&O 2010, 8 (4): 232-3

Good tolerability, long-term survival and easy management of side effects in a patient with metastatic renal cell carcinoma treated with pazopanib. Mara Frascaroli, Pamela Di Cesare Tumori 2014, 100 (6): e301-4

Make the most of Read.
Download the mobile app.

Want full text access to this paper?

Use Read by QxMD to access full text via your institution or open access sources.

Read also provides personalized recommendations to keep you up to date in your field.

Existing User

New to Read

Pazopanib

Discussion

Related Papers

Want full text access to this paper?

Save your favorite articles in one place with a free QxMD account.

Read

Search Tips